1
|
Taneja V, Anand RS, El-Dallal M, Dong J, Desai N, Taneja I, Feuerstein JD. Safety of Biologic and Small Molecule Therapy for Inflammatory Bowel Disease Among Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2024; 30:585-593. [PMID: 37300512 DOI: 10.1093/ibd/izad108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/18/2022] [Indexed: 06/12/2023]
Abstract
BACKGROUND Patients undergoing organ transplantation are often on immunosuppressing medications to prevent rejection of the transplant. The data on use of concomitant immunosuppression for inflammatory bowel disease (IBD) and organ transplant management are limited. This study sought to evaluate the safety of biologic and small molecule therapy for the treatment of IBD among solid organ transplant recipients. METHODS Medline, Embase, and Web of Science databases were systematically searched for studies reporting on safety outcomes associated with the use of biologic and small molecule therapy (infliximab, adalimumab, certolizumab, golimumab, vedolizumab, ustekinumab, and tofacitinib) in patients with IBD postsolid organ transplant (eg, liver, kidney, heart, lung, pancreas). The primary outcome was infectious complications. Secondary outcomes included serious infections, colectomy, and discontinuation of biologic therapy. RESULTS Seven hundred ninety-seven articles were identified for screening, yielding 16 articles for the meta-analyses with information on 163 patients. Antitumor necrosis factor α (Anti-TNFs; infliximab and adalimumab) were used in 8 studies, vedolizumab in 6 studies, and a combination of ustekinumab or vedolizumab and anti-TNFs in 2 studies. Two studies reported outcomes after kidney and cardiac transplant respectively, whereas the rest of the studies included patients with liver transplants. The rates of all infections and serious infections were 20.09 per 100 person-years (100-PY; 95% CI, 12.23-32.99 per 100-PY, I2 = 54%) and 17.39 per 100-PY (95% CI, 11.73-25.78 per 100-PY, I2 = 21%), respectively. The rates of colectomy and biologic medication discontinuation were 12.62 per 100-PY (95% CI, 6.34-25.11 per 100-PY, I2 = 34%) and 19.68 per 100-PY (95% CI, 9.97-38.84 per 100-PY, I2 = 74%), respectively. No cases of venous thromboembolism or death attributable to biologic use were reported. CONCLUSION Biologic therapy is overall well tolerated in patients with solid organ transplant. Long-term studies are needed to better define the role of specific agents in this patient population.
Collapse
Affiliation(s)
- Vikas Taneja
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Rajsavi S Anand
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Mohammed El-Dallal
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
- Cambridge Health Alliance, Harvard Medical School, Boston, MA, USA
| | - Jeffrey Dong
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Nisa Desai
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Isha Taneja
- Massachusetts General Hospital for Children, Harvard Medical School, Boston, MA, USA
| | - Joseph D Feuerstein
- Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
2
|
Bhateria M, Taneja I, Karsauliya K, Sonker AK, Shibata Y, Sato H, Singh SP, Hisaka A. Predicting the in vivo developmental toxicity of fenarimol from in vitro toxicity data using PBTK modelling-facilitated reverse dosimetry approach. Toxicol Appl Pharmacol 2024; 484:116879. [PMID: 38431230 DOI: 10.1016/j.taap.2024.116879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Revised: 02/21/2024] [Accepted: 02/27/2024] [Indexed: 03/05/2024]
Abstract
In vitro methods are widely used in modern toxicological testing; however, the data cannot be directly employed for risk assessment. In vivo toxicity of chemicals can be predicted from in vitro data using physiologically based toxicokinetic (PBTK) modelling-facilitated reverse dosimetry (PBTK-RD). In this study, a minimal-PBTK model was constructed to predict the in-vivo kinetic profile of fenarimol (FNL) in rats and humans. The model was verified by comparing the observed and predicted pharmacokinetics of FNL for rats (calibrator) and further applied to humans. Using the PBTK-RD approach, the reported in vitro developmental toxicity data for FNL was translated to in vivo dose-response data to predict the assay equivalent oral dose in rats and humans. The predicted assay equivalent rat oral dose (36.46 mg/kg) was comparable to the literature reported in vivo BMD10 value (22.8 mg/kg). The model was also employed to derive the chemical-specific adjustment factor (CSAF) for interspecies toxicokinetics variability of FNL. Further, Monte Carlo simulations were performed to predict the population variability in the plasma concentration of FNL and to derive CSAF for intersubject human kinetic differences. The comparison of CSAF values for interspecies and intersubject toxicokinetic variability with their respective default values revealed that the applied uncertainty factors were adequately protective.
Collapse
Affiliation(s)
- Manisha Bhateria
- Toxicokinetics Laboratory, ASSIST and REACT Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India
| | - Isha Taneja
- Certara UK Limited, Simcyp Division, Acero, 1 Concourse Way, Sheffield S1 2BJ, UK
| | - Kajal Karsauliya
- Toxicokinetics Laboratory, ASSIST and REACT Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India
| | - Ashish Kumar Sonker
- Toxicokinetics Laboratory, ASSIST and REACT Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India
| | - Yukihiro Shibata
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8675, Japan
| | - Hiromi Sato
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8675, Japan
| | - Sheelendra Pratap Singh
- Toxicokinetics Laboratory, ASSIST and REACT Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
| | - Akihiro Hisaka
- Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba, 260-8675, Japan
| |
Collapse
|
3
|
Keet CA, Wood RA, Dantzer J, Plesa M, Taneja I, Andre M, Shreffler W, Togias A, Pistiner M. Frequency and predictors of multisystem reactions to peanut in infant oral food challenges. J Allergy Clin Immunol Pract 2024; 12:252-254. [PMID: 37852442 DOI: 10.1016/j.jaip.2023.10.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 09/20/2023] [Accepted: 10/11/2023] [Indexed: 10/20/2023]
Affiliation(s)
- Corinne A Keet
- Division of Pediatric Allergy and Immunology, Department of Pediatrics, University of North Carolina, Chapel Hill, NC.
| | - Robert A Wood
- Division of Pediatric Allergy, Immunology and Rheumatology, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Md
| | - Jennifer Dantzer
- Division of Pediatric Allergy, Immunology and Rheumatology, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Md
| | - Mihaela Plesa
- Division of Pediatric Allergy, Immunology and Rheumatology, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Md
| | - Isha Taneja
- Division of Pediatric Allergy and Immunology, Department of Pediatrics, MassGeneral for Children, Harvard Medical School, Boston, Mass
| | - Mharlove Andre
- Division of Pediatric Allergy and Immunology, Department of Pediatrics, MassGeneral for Children, Harvard Medical School, Boston, Mass
| | - Wayne Shreffler
- Division of Pediatric Allergy and Immunology, Department of Pediatrics, MassGeneral for Children, Harvard Medical School, Boston, Mass
| | - Alkis Togias
- Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Washington, DC
| | - Michael Pistiner
- Division of Pediatric Allergy and Immunology, Department of Pediatrics, MassGeneral for Children, Harvard Medical School, Boston, Mass
| |
Collapse
|
4
|
Ramirez L, Roy I, Taneja I, Yap S, Mendez-Reyes J, Andre M, Hazi A, Esteban C, Ongaro Z, Pan L, Shreffler W, Pistiner M. Systemic Reactions in Infants and Toddlers: A Prospective Study of Oral Food Challenge Outcomes. J Allergy Clin Immunol 2023. [DOI: 10.1016/j.jaci.2022.12.689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
5
|
Fuller A, Taneja I, Roy I, Yap S, Ongaro Z, Randazzo-Ahern N, Scott-Oster S, Hubbard J, Darci K, Pistiner M. Conflicting Messages Regarding Infant Feeding May Encourage Delayed Introduction of Potentially Allergenic Foods. J Allergy Clin Immunol 2023. [DOI: 10.1016/j.jaci.2022.12.328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
6
|
Zhao N, Taneja I, Chung M. Cochrane Review Summary on "Probiotics for Preventing Gestational Diabetes". J Diet Suppl 2021; 19:146-148. [PMID: 34842031 DOI: 10.1080/19390211.2022.2008603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Naisi Zhao
- Department of Public Health and Community Medicine, School of Medicine, Tufts University, Boston, MA, USA
| | - Isha Taneja
- Department of Public Health and Community Medicine, School of Medicine, Tufts University, Boston, MA, USA
| | - Mei Chung
- Friedman School of Nutrition Science and Policy, Tufts University, Boston, MA, USA
| |
Collapse
|
7
|
Chaturvedi S, Malik MY, Sultana N, Jahan S, Singh S, Taneja I, Raju KSR, Rashid M, Wahajuddin M. Chromatographic separation and estimation of natural antimalarial flavonoids in biological matrices. Proc Indian Natl Sci Acad 2021. [DOI: 10.1007/s43538-021-00050-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Taneja V, Taneja I, Mihali AB, Pawar R. Excipient Hypersensitivity Masquerading as Multidrug Allergy. Am J Med 2021; 134:e447-e448. [PMID: 33811872 DOI: 10.1016/j.amjmed.2021.02.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/13/2021] [Revised: 01/30/2021] [Accepted: 02/02/2021] [Indexed: 12/18/2022]
Affiliation(s)
- Vikas Taneja
- Section of Hospital Medicine, Beth Israel Deaconess Medical Center, Boston, Mass.
| | - Isha Taneja
- Tufts University School of Medicine, Boston, Mass
| | | | - Rahul Pawar
- Section of Hospital Medicine, Beth Israel Deaconess Medical Center, Boston, Mass
| |
Collapse
|
9
|
Singh SK, Valicherla GR, Bikkasani AK, Cheruvu SH, Hossain Z, Taneja I, Ahmad H, Raju KSR, Sangwan NS, Singh SK, Dwivedi AK, Wahajuddin M, Gayen JR. Elucidation of plasma protein binding, blood partitioning, permeability, CYP phenotyping and CYP inhibition studies of Withanone using validated UPLC method: An active constituent of neuroprotective herb Ashwagandha. J Ethnopharmacol 2021; 270:113819. [PMID: 33460762 DOI: 10.1016/j.jep.2021.113819] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Revised: 10/01/2020] [Accepted: 01/11/2021] [Indexed: 06/12/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Withanone (WN), an active constituent of Withania somnifera commonly called Ashwagandha has remarkable pharmacological responses along with neurological activities. However, for a better understanding of the pharmacokinetic and pharmacodynamic behavior of WN, a comprehensive in-vitro ADME (absorption, distribution, metabolism, and excretion) studies are necessary. AIM OF THE STUDY A precise, accurate, and sensitive reverse-phase ultra-performance liquid chromatographic method of WN was developed and validated in rat plasma for the first time. The developed method was successfully applied to the in-vitro ADME investigation of WN. MATERIAL AND METHODS The passive permeability of WN was assayed using PAMPA plates and the plasma protein binding (PPB) was performed using the equilibrium dialysis method. Pooled liver microsomes of rat (RLM) and human (HLM) were used for the microsomal stability, CYP phenotyping, and inhibition studies. CYP phenotyping was evaluated using the specific inhibitors. CYP inhibition study was performed using specific probe substrates along with WN or specific inhibitors. RESULTS WN was found to be stable in the simulated gastric and intestinal environment and has a high passive permeability at pH 4.0 and 7.0 in PAMPA assay. The PPB of WN at 5 and 20 μg/mL concentrations were found to be high i.e. 82.01 ± 1.44 and 88.02 ± 1.15%, respectively. The in vitro half-life of WN in RLM and HLM was found to be 59.63 ± 2.50 and 68.42 ± 2.19 min, respectively. CYP phenotyping results showed that WN was extensively metabolized by CYP 3A4 and1A2 enzymes in RLM and HLM. However, the results of CYP Inhibition studies showed that none of the CYP isoenzymes were potentially inhibited by WN in RLM and HLM. CONCLUSION The in vitro results of pH-dependent stability, plasma stability, permeability, PPB, blood partitioning, microsomal stability, CYP phenotyping, and CYP inhibition studies demonstrated that WN could be a better phytochemical for neurological disorders.
Collapse
Affiliation(s)
- Sandeep K Singh
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - Guru R Valicherla
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - Anil K Bikkasani
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (R), Lucknow, 226301, India
| | - Srikanth H Cheruvu
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India
| | - Zakir Hossain
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India
| | - Isha Taneja
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - Hafsa Ahmad
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India
| | - Kanumuri S R Raju
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India
| | - Neelam S Sangwan
- CSIR-Central Institute of Medicinal and Aromatic Plants, Lucknow, 226015, India
| | - Shio K Singh
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - Anil K Dwivedi
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India
| | - Mohammad Wahajuddin
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - Jiaur R Gayen
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.
| |
Collapse
|
10
|
Karsauliya K, Sonker AK, Bhateria M, Taneja I, Srivastava A, Sharma M, Singh SP. Plasma protein binding, metabolism, reaction phenotyping and toxicokinetic studies of fenarimol after oral and intravenous administration in rats. Xenobiotica 2020; 51:72-81. [PMID: 32660295 DOI: 10.1080/00498254.2020.1796170] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Fenarimol (FNL), an organic chlorinated fungicide, is widely used in agriculture for protection from fungal spores and fungi. Despite being an endocrine disruptor, no toxicokinetic data is reported for this fungicide. In the present work, we determined the plasma protein binding, metabolic pathways and toxicokinetics of FNL in rats. In vitro binding of FNL to rat and human plasma proteins was ∼90%, suggesting that FNL is a highly protein bound fungicide. The predicted in vivo hepatic clearance of FNL in rats and humans was estimated to be 36.71 and 14.39 mL/min/kg, respectively, indicating it to be an intermediate clearance compound. Reaction phenotyping assay showed that CYP3A4 mainly contributed to the overall metabolism of FNL. The oral toxicokinetic study of FNL in rats at no observed adverse effect level dose (1 mg/kg) showed maximum plasma concentration (C max) of 33.97 ± 4.45 ng/mL at 1 h (T max). The AUC0-∞ obtained was 180.18 ± 17.76 h*ng/mL, whereas, the t 1/2 was ∼4.74 h. Following intravenous administration, FNL displayed a clearance of 42.48 mL/min/kg which was close to the predicted in vivo hepatic clearance. The absolute oral bioavailability of FNL at 1 mg/kg dose in rats was 45.25%. FNL at 10 mg/kg oral dose exhibited non-linear toxicokinetics with greater than dose-proportional increase in the systemic exposure (AUC0-∞ 8270.53 ± 1798.59 h*ng/mL).
Collapse
Affiliation(s)
- Kajal Karsauliya
- Pesticide Toxicology Laboratory & Regulatory Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India.,Department of Pharmacy, Banasthali Vidyapith, Banasthali, India
| | - Ashish Kumar Sonker
- Pesticide Toxicology Laboratory & Regulatory Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India
| | - Manisha Bhateria
- Pesticide Toxicology Laboratory & Regulatory Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India
| | - Isha Taneja
- Simcyp Division, Certara UK Limited, Sheffield, UK
| | - Anshuman Srivastava
- Pesticide Toxicology Laboratory & Regulatory Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India
| | - Manu Sharma
- Department of Pharmacy, Banasthali Vidyapith, Banasthali, India
| | - Sheelendra Pratap Singh
- Pesticide Toxicology Laboratory & Regulatory Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.,Analytical Chemistry Laboratory & Regulatory Toxicology Group, CSIR-Indian Institute of Toxicology Research (CSIR-IITR), Lucknow, India
| |
Collapse
|
11
|
Taneja I, Raghuvanshi A, Rama Raju KS, Awasthi P, Rashid M, Singh S, Goel A, Singh SP, Wahajuddin M. Bioavailability, tissue distribution and excretion studies of a potential anti-osteoporotic agent, medicarpin, in female rats using validated LC-MS/MS method. J Pharm Biomed Anal 2020; 180:112978. [PMID: 31855725 DOI: 10.1016/j.jpba.2019.112978] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2019] [Revised: 10/24/2019] [Accepted: 11/08/2019] [Indexed: 11/28/2022]
Abstract
Medicarpin, one of the active constituents isolated from the extract of Butea monosperma, has been shown to have various pharmacological activities including potent anti-osteoporotic properties. The aim of this study was to investigate the oral pharmacokinetics, tissue distribution and excretion of medicarpin following single oral dose administration in female rats. Oral pharmacokinetics was explored at 5 and 20 mg/kg while tissue distribution, urinary and fecal excretion were studied following 20 mg/kg oral dose. Medicarpin was quantified in rat plasma, urine, feces and tissue samples using a validated LC-MS/MS method following reverse-phase HPLC separation on RP18 column (4.6 mm × 50 mm, 5.0 μm) using methanol and 10 mM ammonium acetate (pH 4.0) as mobile phase in the ratio of 80:20 (v/v) at a flow rate of 0.8 mL/min. The oral bioavailability of medicarpin was found to be low with low systemic levels. The concentration in tissues was significantly higher than plasma. Highest tissue concentrations were found in the liver followed by bone marrow. Urinary and fecal excretion of medicarpin was < 1 %. In conclusion, medicarpin was found to be highly distributed in body tissues and minimally excreted via urine or feces.
Collapse
Affiliation(s)
- Isha Taneja
- Academcy of Scientific and Innovative Research, New Delhi, India; Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India
| | - Ashutosh Raghuvanshi
- Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India
| | - Kanumuri Siva Rama Raju
- Academcy of Scientific and Innovative Research, New Delhi, India; Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India
| | - Pallavi Awasthi
- Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India
| | - Mamunur Rashid
- Academcy of Scientific and Innovative Research, New Delhi, India; Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India
| | - Sandeep Singh
- Academcy of Scientific and Innovative Research, New Delhi, India; Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India
| | - Atul Goel
- Academcy of Scientific and Innovative Research, New Delhi, India; Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India
| | - Sheelendra Pratap Singh
- Pesticide Toxicology Laboratory, Regulatory Toxicology and Nanotherapeutics & Nanomaterial Toxicology Group, CSIR-Indian Institute of Toxicology Research, Lucknow, 226001, India.
| | - Muhammad Wahajuddin
- Academcy of Scientific and Innovative Research, New Delhi, India; Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, 226031, India.
| |
Collapse
|
12
|
Raju KSR, Rashid M, Gundeti M, Taneja I, Malik MY, Singh SK, Chaturvedi S, Challagundla M, Singh SP, Gayen JR, Wahajuddin M. LC-ESI-MS/MS method for the simultaneous determination of isoformononetin, daidzein, and equol in rat plasma: Application to a preclinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1129:121776. [PMID: 31629309 DOI: 10.1016/j.jchromb.2019.121776] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Revised: 08/07/2019] [Accepted: 08/23/2019] [Indexed: 11/16/2022]
Abstract
Isoformononetin (methoxy isoflavone) is a potent osteogenic isoflavone abundantly present in Butea monosperma, Pisum sativum, Mung bean, Machaerium villosum, Medicago sativa, and Glycine max. In the current study, an LC-ESI-MS/MS method for the simultaneous evaluation of isoformononetin (IFN), daidzein (DZN) and equol (EQL) was developed and validated in rat plasma using biochanin A as an internal standard. IFN, DZN, and EQL separation was achieved by using acetonitrile and acetic acid (0.1%) in the ratio of 90:10 (% v/v) as mobile phase under isocratic conditions at a flow rate of 0.6 mL/min on Atlantis C18 (4.6 × 250 mm, 5.0 μm) column. The achieved method was linear within the concentration range of 0.5-500 ng/mL. The method was effectively applied to investigate the permeability, protein binding estimation and pharmacokinetics studies of IFN in rats. The PAMPA permeability of IFN was found to be high at pH 4.0 and 7.0. The protein binding was found to be about 91% of IFN. The oral bioavailability of IFN was found to be poor (21.6%). IFN was found to have a moderate clearance (2.9 L/h/kg) and a large apparent volume of distribution (12.1 L/kg). The plasma half-life (t1/2) and maximum attainable concentration (Cmax) of IFN at systemic circulation was found to be 1.9 ± 0.6 h and 269.3 ± 0.4 after oral administration.
Collapse
Affiliation(s)
- Kanumuri Siva Rama Raju
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India; Academy of Scientific and Innovative Research, New Delhi, India; Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, USA
| | - Mamunur Rashid
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India
| | - Manoj Gundeti
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India
| | - Isha Taneja
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India; Academy of Scientific and Innovative Research, New Delhi, India; Certara UK Limited, Simcyp Division, Acero, 1 Concourse Way, Sheffield S1 2BJ, UK
| | - Mohd Yaseen Malik
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India
| | - Sandeep Kumar Singh
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India; Academy of Scientific and Innovative Research, New Delhi, India
| | - Swati Chaturvedi
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India; Academy of Scientific and Innovative Research, New Delhi, India
| | | | | | - J R Gayen
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India
| | - Muhammad Wahajuddin
- Pharmaceutics & Pharmacokinetics Division, CSIR-Central Drug Research Institute, Lucknow, India; Academy of Scientific and Innovative Research, New Delhi, India.
| |
Collapse
|
13
|
Rashid M, Singh SK, Malik MY, Jahan S, Chaturvedi S, Taneja I, Raju KS, Naseem Z, Gayen J, Wahajuddin M. Development and validation of UPLC-MS/MS assay for quantification of cladrin: Absolute bioavailability and dose proportionality study in rats. J Pharm Biomed Anal 2018; 152:289-297. [DOI: 10.1016/j.jpba.2018.01.044] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Revised: 01/11/2018] [Accepted: 01/21/2018] [Indexed: 12/19/2022]
|
14
|
Yaseen Malik M, Taneja I, Raju KSR, Rahaman Gayen J, Singh SP, Sangwand NS, Wahajuddin M. RP-HPLC Separation of Isomeric Withanolides: Method Development, Validation and Application to In situ Rat Permeability Determination. J Chromatogr Sci 2017; 55:729-735. [DOI: 10.1093/chromsci/bmx027] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2016] [Indexed: 11/14/2022]
Affiliation(s)
- Mohd Yaseen Malik
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, India
| | - Isha Taneja
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, India
- Academy of Scientific & Innovative Research, New Delhi 110020, India
| | - Kanumuri Siva Rama Raju
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, India
- Academy of Scientific & Innovative Research, New Delhi 110020, India
| | - Jiaur Rahaman Gayen
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, India
- Academy of Scientific & Innovative Research, New Delhi 110020, India
| | - Sheelendra Pratap Singh
- Pesticide Toxicology Laboratory, Regulatory Toxicology and Nanotherapeutics & Nanomaterial Toxicology Group, CSIR-Indian Institute of Toxicology Research, Lucknow 226001, India
| | - Neelam S. Sangwand
- Division of Metabolic and Structural Biology, CSIR-Central Institute of Medicinal and Aromatic Plants, Luckow, India
| | - Muhammad Wahajuddin
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, India
- Academy of Scientific & Innovative Research, New Delhi 110020, India
| |
Collapse
|
15
|
Anand D, Yadav PK, Patel OPS, Parmar N, Maurya RK, Vishwakarma P, Raju KSR, Taneja I, Wahajuddin M, Kar S, Yadav PP. Antileishmanial Activity of Pyrazolopyridine Derivatives and Their Potential as an Adjunct Therapy with Miltefosine. J Med Chem 2017; 60:1041-1059. [DOI: 10.1021/acs.jmedchem.6b01447] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
| | - Pawan Kumar Yadav
- Academy of Scientific and Innovative Research, Anusandhan Bhawan, New Delhi 110025, India
| | | | - Naveen Parmar
- Academy of Scientific and Innovative Research, Anusandhan Bhawan, New Delhi 110025, India
| | | | - Preeti Vishwakarma
- Academy of Scientific and Innovative Research, Anusandhan Bhawan, New Delhi 110025, India
| | - Kanumuri S. R. Raju
- Academy of Scientific and Innovative Research, Anusandhan Bhawan, New Delhi 110025, India
| | - Isha Taneja
- Academy of Scientific and Innovative Research, Anusandhan Bhawan, New Delhi 110025, India
| | - M. Wahajuddin
- Academy of Scientific and Innovative Research, Anusandhan Bhawan, New Delhi 110025, India
| | - Susanta Kar
- Academy of Scientific and Innovative Research, Anusandhan Bhawan, New Delhi 110025, India
| | - Prem P. Yadav
- Academy of Scientific and Innovative Research, Anusandhan Bhawan, New Delhi 110025, India
| |
Collapse
|
16
|
Raju KSR, Gundeti M, Malik MY, Kadian N, Rashid M, Taneja I, Singh SP, Wahajuddin M. Bioanalysis of antitubercular drugs using liquid chromatography. J Pharm Biomed Anal 2016; 134:295-309. [PMID: 27951471 DOI: 10.1016/j.jpba.2016.11.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2016] [Revised: 11/01/2016] [Accepted: 11/08/2016] [Indexed: 11/17/2022]
Abstract
Tuberculosis is a life threatening disease and second to HIV in terms of deaths due to infectious diseases. Drug resistance development of the first-line drugs is a major concern in the treatment of this disease. There is no comprehensive and critical review in the literature of the bioanalytical methods for the determination of anti-tubercular agents from last two decades. This work offers a detailed account on the liquid chromatographic methods reported in the literature for the estimation of various anti-tubercular drugs. Major emphasis is given to sample preparation process, sensitivity of method, chromatographic separation conditions and detection systems used in their bioanalysis.
Collapse
Affiliation(s)
- Kanumuri Siva Rama Raju
- Academy of Scientific and Innovative Research, New Delhi, India; Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India
| | - Manoj Gundeti
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Raebareli, India
| | - Mohd Yaseen Malik
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India
| | - Naveen Kadian
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India
| | - Mamunur Rashid
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India
| | - Isha Taneja
- Academy of Scientific and Innovative Research, New Delhi, India; Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India
| | | | - Muhammad Wahajuddin
- Academy of Scientific and Innovative Research, New Delhi, India; Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India; Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Raebareli, India.
| |
Collapse
|
17
|
Patel OPS, Mishra A, Maurya R, Saini D, Pandey J, Taneja I, Raju KSR, Kanojiya S, Shukla SK, Srivastava MN, Wahajuddin M, Tamrakar AK, Srivastava AK, Yadav PP. Naturally Occurring Carbazole Alkaloids from Murraya koenigii as Potential Antidiabetic Agents. J Nat Prod 2016; 79:1276-1284. [PMID: 27136692 DOI: 10.1021/acs.jnatprod.5b00883] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
This study identified koenidine (4) as a metabolically stable antidiabetic compound, when evaluated in a rodent type 2 model (leptin receptor-deficient db/db mice), and showed a considerable reduction in the postprandial blood glucose profile with an improvement in insulin sensitivity. Biological studies were directed from the preliminary in vitro evaluation of the effects of isolated carbazole alkaloids (1-6) on glucose uptake and GLUT4 translocation in L6-GLUT4myc myotubes, followed by an investigation of their activity (2-5) in streptozotocin-induced diabetic rats. The effect of koenidine (4) on GLUT4 translocation was mediated by the AKT-dependent signaling pathway in L6-GLUT4myc myotubes. Moreover, in vivo pharmacokinetic studies of compounds 2 and 4 clearly showed that compound 4 was 2.7 times more bioavailable than compound 2, resulting in a superior in vivo efficacy. Therefore, these studies suggested that koenidine (4) may serve as a promising lead natural scaffold for managing insulin resistance and diabetes.
Collapse
Affiliation(s)
- Om P S Patel
- Division of Medicinal and Process Chemistry, ‡Division of Biochemistry, §Division of Pharmacokinetics and Metabolism, ∥Sophisticated Analytical Instrument Facility, and ⊥Division of Botany, CSIR-Central Drug Research Institute , Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - Akansha Mishra
- Division of Medicinal and Process Chemistry, ‡Division of Biochemistry, §Division of Pharmacokinetics and Metabolism, ∥Sophisticated Analytical Instrument Facility, and ⊥Division of Botany, CSIR-Central Drug Research Institute , Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - Ranjani Maurya
- Division of Medicinal and Process Chemistry, ‡Division of Biochemistry, §Division of Pharmacokinetics and Metabolism, ∥Sophisticated Analytical Instrument Facility, and ⊥Division of Botany, CSIR-Central Drug Research Institute , Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - Deepika Saini
- Division of Medicinal and Process Chemistry, ‡Division of Biochemistry, §Division of Pharmacokinetics and Metabolism, ∥Sophisticated Analytical Instrument Facility, and ⊥Division of Botany, CSIR-Central Drug Research Institute , Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - Jyotsana Pandey
- Division of Medicinal and Process Chemistry, ‡Division of Biochemistry, §Division of Pharmacokinetics and Metabolism, ∥Sophisticated Analytical Instrument Facility, and ⊥Division of Botany, CSIR-Central Drug Research Institute , Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - Isha Taneja
- Division of Medicinal and Process Chemistry, ‡Division of Biochemistry, §Division of Pharmacokinetics and Metabolism, ∥Sophisticated Analytical Instrument Facility, and ⊥Division of Botany, CSIR-Central Drug Research Institute , Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - Kanumuri S R Raju
- Division of Medicinal and Process Chemistry, ‡Division of Biochemistry, §Division of Pharmacokinetics and Metabolism, ∥Sophisticated Analytical Instrument Facility, and ⊥Division of Botany, CSIR-Central Drug Research Institute , Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - Sanjeev Kanojiya
- Division of Medicinal and Process Chemistry, ‡Division of Biochemistry, §Division of Pharmacokinetics and Metabolism, ∥Sophisticated Analytical Instrument Facility, and ⊥Division of Botany, CSIR-Central Drug Research Institute , Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - Sanjeev K Shukla
- Division of Medicinal and Process Chemistry, ‡Division of Biochemistry, §Division of Pharmacokinetics and Metabolism, ∥Sophisticated Analytical Instrument Facility, and ⊥Division of Botany, CSIR-Central Drug Research Institute , Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - Mahendra N Srivastava
- Division of Medicinal and Process Chemistry, ‡Division of Biochemistry, §Division of Pharmacokinetics and Metabolism, ∥Sophisticated Analytical Instrument Facility, and ⊥Division of Botany, CSIR-Central Drug Research Institute , Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - M Wahajuddin
- Division of Medicinal and Process Chemistry, ‡Division of Biochemistry, §Division of Pharmacokinetics and Metabolism, ∥Sophisticated Analytical Instrument Facility, and ⊥Division of Botany, CSIR-Central Drug Research Institute , Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - Akhilesh K Tamrakar
- Division of Medicinal and Process Chemistry, ‡Division of Biochemistry, §Division of Pharmacokinetics and Metabolism, ∥Sophisticated Analytical Instrument Facility, and ⊥Division of Botany, CSIR-Central Drug Research Institute , Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - Arvind K Srivastava
- Division of Medicinal and Process Chemistry, ‡Division of Biochemistry, §Division of Pharmacokinetics and Metabolism, ∥Sophisticated Analytical Instrument Facility, and ⊥Division of Botany, CSIR-Central Drug Research Institute , Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| | - Prem P Yadav
- Division of Medicinal and Process Chemistry, ‡Division of Biochemistry, §Division of Pharmacokinetics and Metabolism, ∥Sophisticated Analytical Instrument Facility, and ⊥Division of Botany, CSIR-Central Drug Research Institute , Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India
| |
Collapse
|
18
|
Wahajuddin M, Taneja I, Raju K, Rashid M. Pharmacokinetic endeavors for antimalarial therapeutics. Int J Infect Dis 2016. [DOI: 10.1016/j.ijid.2016.02.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
19
|
Kadian N, Raju KSR, Rashid M, Malik MY, Taneja I, Wahajuddin M. Comparative assessment of bioanalytical method validation guidelines for pharmaceutical industry. J Pharm Biomed Anal 2016; 126:83-97. [PMID: 27179186 DOI: 10.1016/j.jpba.2016.03.052] [Citation(s) in RCA: 97] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Accepted: 03/24/2016] [Indexed: 10/22/2022]
Abstract
The concepts, importance, and application of bioanalytical method validation have been discussed for a long time and validation of bioanalytical methods is widely accepted as pivotal before they are taken into routine use. United States Food and Drug Administration (USFDA) guidelines issued in 2001 have been referred for every guideline released ever since; may it be European Medical Agency (EMA) Europe, National Health Surveillance Agency (ANVISA) Brazil, Ministry of Health and Labour Welfare (MHLW) Japan or any other guideline in reference to bioanalytical method validation. After 12 years, USFDA released its new draft guideline for comments in 2013, which covers the latest parameters or topics encountered in bioanalytical method validation and approached towards the harmonization of bioanalytical method validation across the globe. Even though the regulatory agencies have general agreement, significant variations exist in acceptance criteria and methodology. The present review highlights the variations, similarities and comparison between bioanalytical method validation guidelines issued by major regulatory authorities worldwide. Additionally, other evaluation parameters such as matrix effect, incurred sample reanalysis including other stability aspects have been discussed to provide an ease of access for designing a bioanalytical method and its validation complying with the majority of drug authority guidelines.
Collapse
Affiliation(s)
- Naveen Kadian
- Department of Pharmacokinetics and Metabolism, CSIR-Central Drug Research Institute, Lucknow, India
| | - Kanumuri Siva Rama Raju
- Department of Pharmacokinetics and Metabolism, CSIR-Central Drug Research Institute, Lucknow, India; Academy of Scientific and Industrial Research, New Delhi, India
| | - Mamunur Rashid
- Department of Pharmacokinetics and Metabolism, CSIR-Central Drug Research Institute, Lucknow, India
| | - Mohd Yaseen Malik
- Department of Pharmacokinetics and Metabolism, CSIR-Central Drug Research Institute, Lucknow, India
| | - Isha Taneja
- Department of Pharmacokinetics and Metabolism, CSIR-Central Drug Research Institute, Lucknow, India; Academy of Scientific and Industrial Research, New Delhi, India
| | - Muhammad Wahajuddin
- Department of Pharmacokinetics and Metabolism, CSIR-Central Drug Research Institute, Lucknow, India; Academy of Scientific and Industrial Research, New Delhi, India.
| |
Collapse
|
20
|
Raju KSR, Taneja I, Rashid M, Sonkar AK, Wahajuddin M, Singh SP. DBS-platform for biomonitoring and toxicokinetics of toxicants: proof of concept using LC-MS/MS analysis of fipronil and its metabolites in blood. Sci Rep 2016; 6:22447. [PMID: 26960908 PMCID: PMC4785372 DOI: 10.1038/srep22447] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Accepted: 02/09/2016] [Indexed: 11/09/2022] Open
Abstract
A simple, sensitive and high throughput LC-MS/MS method was developed and validated for quantification of fipronil, fipronil sulfone and fipronil desulfinyl in rat and human dried blood spots (DBS). DBS samples were prepared by spiking 10 μl blood on DMPK-C cards followed by drying at room temperature. The whole blood spots were then punched from the card and extracted using acetonitrile. The total chromatographic run time of the method was only 2 min. The lower limit of quantification of the method was 0.1 ng/ml for all the analytes. The method was successfully applied to determine fipronil desulfinyl in DBS samples obtained from its toxicokinetic study in rats following intravenous dose (1 mg/kg). In conclusion, the proposed DBS methodology has significant potential in toxicokinetics and biomonitoring studies of environmental toxicants. This microvolume DBS technique will be an ideal tool for biomonitoring studies, particularly in paediatric population. Small volume requirements, minimally invasive blood sampling method, easier storage and shipping procedure make DBS a suitable technique for such studies. Further, DBS technique contributes towards the principles of 3Rs resulting in significant reduction in the number of rodents used and refinement in sample collection for toxicokinetic studies.
Collapse
Affiliation(s)
- Kanumuri Siva Rama Raju
- Pharmacokinetics and Metabolism Division, CSIR- Central Drug Research Institute, Lucknow-226031, India
| | - Isha Taneja
- Pharmacokinetics and Metabolism Division, CSIR- Central Drug Research Institute, Lucknow-226031, India
| | - Mamunur Rashid
- Pharmacokinetics and Metabolism Division, CSIR- Central Drug Research Institute, Lucknow-226031, India
| | - Ashish Kumar Sonkar
- Academy of Scientific and Innovative Research (AcSIR), CSIR-IITR Campus, Lucknow, India.,Analytical Chemistry Laboratory, Regulatory Toxicology and Nanotherapeutics &Nanomaterial Toxicology Group, CSIR-Indian Institute of Toxicology Research, Vishvigyan Bhavan, 31, Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India
| | - Muhammad Wahajuddin
- Pharmacokinetics and Metabolism Division, CSIR- Central Drug Research Institute, Lucknow-226031, India
| | - Sheelendra Pratap Singh
- Academy of Scientific and Innovative Research (AcSIR), CSIR-IITR Campus, Lucknow, India.,Analytical Chemistry Laboratory, Regulatory Toxicology and Nanotherapeutics &Nanomaterial Toxicology Group, CSIR-Indian Institute of Toxicology Research, Vishvigyan Bhavan, 31, Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India
| |
Collapse
|
21
|
Pal S, Khan K, China SP, Mittal M, Porwal K, Shrivastava R, Taneja I, Hossain Z, Mandalapu D, Gayen JR, Wahajuddin M, Sharma VL, Trivedi AK, Sanyal S, Bhadauria S, Godbole MM, Gupta SK, Chattopadhyay N. Theophylline, a methylxanthine drug induces osteopenia and alters calciotropic hormones, and prophylactic vitamin D treatment protects against these changes in rats. Toxicol Appl Pharmacol 2016; 295:12-25. [PMID: 26851681 DOI: 10.1016/j.taap.2016.02.002] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2015] [Accepted: 02/02/2016] [Indexed: 12/13/2022]
Abstract
The drug, theophylline is frequently used as an additive to medications for people suffering from chronic obstructive pulmonary diseases (COPD). We studied the effect of theophylline in bone cells, skeleton and parameters related to systemic calcium homeostasis. Theophylline induced osteoblast apoptosis by increasing reactive oxygen species production that was caused by increased cAMP production. Bone marrow levels of theophylline were higher than its serum levels, indicating skeletal accumulation of this drug. When adult Sprague-Dawley rats were treated with theophylline, bone regeneration at fracture site was diminished compared with control. Theophylline treatment resulted in a time-dependent (at 4- and 8 weeks) bone loss. At 8 weeks, a significant loss of bone mass and deterioration of microarchitecture occurred and the severity was comparable to methylprednisone. Theophylline caused formation of hypomineralized osteoid and increased osteoclast number and surface. Serum bone resorption and formation marker were respectively higher and lower in the theophylline group compared with control. Bone strength was reduced by theophylline treatment. After 8 weeks, serum 25-D3 and liver 25-hydroxylases were decreased in theophylline group than control. Further, theophylline treatment reduced serum 1, 25-(OH)2 vitamin D3 (1,25-D3), and increased parathyroid hormone and fibroblast growth factor-23. Theophylline treated rats had normal serum calcium and phosphate but displayed calciuria and phosphaturia. Co-administration of 25-D3 with theophylline completely abrogated theophylline-induced osteopenia and alterations in calcium homeostasis. In addition, 1,25-D3 protected osteoblasts from theophylline-induced apoptosis and the attendant oxidative stress. We conclude that theophylline has detrimental effects in bone and prophylactic vitamin D supplementation to subjects taking theophylline could be osteoprotective.
Collapse
Affiliation(s)
- Subhashis Pal
- Division of Endocrinology and Center for Research in Anabolic Skeletal Target in Health and Illness (ASTHI), Central Drug Research Institute (CDRI), Council of Scientific and Industrial Research (CSIR), Lucknow 226021, India
| | - Kainat Khan
- Division of Endocrinology and Center for Research in Anabolic Skeletal Target in Health and Illness (ASTHI), Central Drug Research Institute (CDRI), Council of Scientific and Industrial Research (CSIR), Lucknow 226021, India
| | - Shyamsundar Pal China
- Division of Endocrinology and Center for Research in Anabolic Skeletal Target in Health and Illness (ASTHI), Central Drug Research Institute (CDRI), Council of Scientific and Industrial Research (CSIR), Lucknow 226021, India
| | - Monika Mittal
- Division of Endocrinology and Center for Research in Anabolic Skeletal Target in Health and Illness (ASTHI), Central Drug Research Institute (CDRI), Council of Scientific and Industrial Research (CSIR), Lucknow 226021, India
| | - Konica Porwal
- Division of Endocrinology and Center for Research in Anabolic Skeletal Target in Health and Illness (ASTHI), Central Drug Research Institute (CDRI), Council of Scientific and Industrial Research (CSIR), Lucknow 226021, India
| | | | - Isha Taneja
- Pharmacokinetics and Metabolism Division, CDRI-CSIR, Lucknow 226021, India
| | - Zakir Hossain
- Pharmacokinetics and Metabolism Division, CDRI-CSIR, Lucknow 226021, India
| | - Dhanaraju Mandalapu
- Division of Medicinal and Process Chemistry, CDRI-CSIR, Lucknow 226021, India
| | - Jiaur R Gayen
- Pharmacokinetics and Metabolism Division, CDRI-CSIR, Lucknow 226021, India
| | | | - Vishnu Lal Sharma
- Division of Medicinal and Process Chemistry, CDRI-CSIR, Lucknow 226021, India
| | - Arun K Trivedi
- Division of Biochemistry, CDRI-CSIR, Lucknow 226021, India
| | | | | | - Madan M Godbole
- Department of Medical Endocrinology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
| | - Sushil K Gupta
- Department of Medical Endocrinology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India
| | - Naibedya Chattopadhyay
- Division of Endocrinology and Center for Research in Anabolic Skeletal Target in Health and Illness (ASTHI), Central Drug Research Institute (CDRI), Council of Scientific and Industrial Research (CSIR), Lucknow 226021, India.
| |
Collapse
|
22
|
Singh SP, Dwivedi N, Raju KSR, Taneja I, Wahajuddin M. Validation of a Rapid and Sensitive UPLC-MS-MS Method Coupled with Protein Precipitation for the Simultaneous Determination of Seven Pyrethroids in 100 µL of Rat Plasma by Using Ammonium Adduct as Precursor Ion. J Anal Toxicol 2016; 40:213-21. [PMID: 26801239 DOI: 10.1093/jat/bkw002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
United States Environmental Protection Agency has recommended estimating pyrethroids' risk using cumulative exposure. For cumulative risk assessment, it would be useful to have a bioanalytical method for quantification of one or several pyrethroids simultaneously in a small sample volume to support toxicokinetic studies. Therefore, in the present study, a simple, sensitive and high-throughput ultraperformance liquid chromatography-tandem mass spectrometry method was developed and validated for simultaneous analysis of seven pyrethroids (fenvalerate, fenpropathrin, bifenthrin, lambda-cyhalothrin, cyfluthrin, cypermethrin and deltamethrin) in 100 µL of rat plasma. A simple single-step protein precipitation method was used for the extraction of target compounds. The total chromatographic run time of the method was 5 min. The chromatographic system used a Supelco C18 column and isocratic elution with a mobile phase consisting of methanol and 5 mM ammonium formate in the ratio of 90 : 10 (v/v). Mass spectrometer (API 4000) was operated in multiple reaction monitoring positive-ion mode using the electrospray ionization technique. The calibration curves were linear in the range of 7.8-2,000 ng/mL with correlation coefficients of ≥ 0.99. All validation parameters such as precision, accuracy, recovery, matrix effect and stability met the acceptance criteria according to the regulatory guidelines. The method was successfully applied to the toxicokinetic study of cypermethrin in rats. To the best of our knowledge, this is the first LC-MS-MS method for the simultaneous analysis of pyrethroids in rat plasma. This validated method with minimal modification can also be utilized for forensic and clinical toxicological applications due to its simplicity, sensitivity and rapidity.
Collapse
Affiliation(s)
- Sheelendra Pratap Singh
- Analytical Chemistry Laboratory and Regulatory Toxicology Group, CSIR-Indian Institute of Toxicology Research, Vishvigyan Bhavan, 31, Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India
| | - Nistha Dwivedi
- Analytical Chemistry Laboratory and Regulatory Toxicology Group, CSIR-Indian Institute of Toxicology Research, Vishvigyan Bhavan, 31, Mahatma Gandhi Marg, Lucknow 226001, Uttar Pradesh, India
| | - Kanumuri Siva Rama Raju
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, Uttar Pradesh, India
| | - Isha Taneja
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, Uttar Pradesh, India
| | - Mohammad Wahajuddin
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, Uttar Pradesh, India
| |
Collapse
|
23
|
Taneja I, Raju KSR, Wahajuddin M. Dietary Isoflavones as Modulators of Drug Metabolizing Enzymes and Transporters: Effect on Prescription Medicines. Crit Rev Food Sci Nutr 2015; 56 Suppl 1:S95-S109. [DOI: 10.1080/10408398.2015.1045968] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
24
|
Taneja I, Raju KSR, Challagundla M, Raghuvanshi A, Goel A, Wahajuddin M. LC-ESI–MS/MS method for bioanalytical determination of osteogenic phytoalexin, medicarpin, and its application to preliminary pharmacokinetic studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci 2015; 1001:9-16. [DOI: 10.1016/j.jchromb.2015.06.025] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Revised: 06/19/2015] [Accepted: 06/21/2015] [Indexed: 10/23/2022]
|
25
|
Arora S, Taneja I, Challagundla M, Raju KSR, Singh SP, Wahajuddin M. In vivo prediction of CYP-mediated metabolic interaction potential of formononetin and biochanin A using in vitro human and rat CYP450 inhibition data. Toxicol Lett 2015; 239:1-8. [PMID: 26278343 DOI: 10.1016/j.toxlet.2015.08.202] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2015] [Revised: 08/10/2015] [Accepted: 08/11/2015] [Indexed: 11/28/2022]
Abstract
Formononetin (FMN) and Biochanin A (BCA) are the principal isoflavones present in commercially available extracts of red clover that are widely been consumed for various health benefits. We investigated the in vitro effects of FMN and BCA on catalytic activity of human/rat cytochrome P450 enzymes to assess the drug interaction potential of red clover. IC50 and Ki values of FMN and BCA for CYPs were determined in human/rat liver microsomes. FMN and BCA showed concentration-dependent inhibition of CYP1A2 activity with IC50 values of 13.42 and 24.98μM in human liver microsomes and 38.57 and 11.86μM in rat liver microsomes, respectively. The mode of inhibition of human CYP1A2 by FMN was found to be competitive with apparent Ki value of 10.13±1.96μM. FMN also inhibited human CYP2D6. BCA exerted moderately inhibitory effects on human CYP2C9. The predicted in vivo inhibition for CYP1A2 was insignificant (R value <1.1) at hepatic level while at intestinal level, it was significant (R value >11). The inhibitory effects on other CYPs were found to be minimal. Red clover may be considered safe to be consumed along with co-prescribed medications; however, precaution must be taken while co-administering it with CYP1A2 substrates.
Collapse
Affiliation(s)
- Sumit Arora
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, Uttar Pradesh, India
| | - Isha Taneja
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, Uttar Pradesh, India; Academy of Scientific and Innovative Research, New Delhi, India
| | | | - Kanumuri Siva Rama Raju
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, Uttar Pradesh, India; Academy of Scientific and Innovative Research, New Delhi, India
| | - Sheelendra Pratap Singh
- Analytical Chemistry Division, CSIR-Indian Institute of Toxicology Research, Lucknow 226001, Uttar Pradesh, India.
| | - Muhammad Wahajuddin
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow 226031, Uttar Pradesh, India; Academy of Scientific and Innovative Research, New Delhi, India; National Institute of Pharmaceutical Research and Education, Raebareli, India.
| |
Collapse
|
26
|
Wahajuddin M, Singh SP, Taneja I, Raju KSR, Gayen JR, Siddiqui HH, Singh SK. Development and validation of an LC-MS/MS method for simultaneous determination of piperaquine and 97-63, the active metabolite of CDRI 97-78, in rat plasma and its application in interaction study. Drug Test Anal 2015; 8:221-7. [PMID: 25975936 DOI: 10.1002/dta.1807] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2014] [Revised: 03/13/2015] [Accepted: 04/01/2015] [Indexed: 11/08/2022]
Abstract
Piperaquine-dihydroartemisinin combination is the latest addition to the repertoire of ACTs recommended by the World Health Organization (WHO) for treatment of falciparum malaria. Due to the increasing resistance to artemisinin derivatives, CSIR-CDRI has developed a prospective short acting, trioxane antimalarial derivative, CDRI 97-78. In the present study, a liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) method for the simultaneous quantification of piperaquine (PPQ) and 97-63, the active metabolite of CDRI 97-78 found in vivo, was developed and validated in 100 μL rat plasma using halofantrine as internal standard. PPQ and 97-63 were separated using acetonitrile:methanol (50:50, v/v) and ammonium formate buffer (10 mM, pH 4.5) in the ratio of 95:5(v/v) as mobile phase under isocratic conditions at a flow rate of 0.65 mL/min on Waters Atlantis C18 (4.6 × 50 mm, 5.0 µm) column. The extraction recoveries of PPQ and 97-63 ranged from 90.58 to 105.48%, while for the internal standard, it was 94.27%. The method was accurate and precise in the linearity range 3.9-250 ng/mL for both the analytes, with a correlation coefficient (r) of ≥ 0.998. The intra- and inter-day assay precision ranged from 2.91 to 8.45% and; intra- and inter-day assay accuracy was between 92.50 and 110.20% for both the analytes. The method was successfully applied to study the effect of oral co-administration of PPQ on the pharmacokinetics of CDRI 97-78 in Sprague-dawley rats and vice versa. The co-administration of CDRI 97-78 caused significant decrease in AUC0-∞ of PPQ from 31.52 ± 2.68 to 14.84 ± 4.33 h*µg/mL. However, co-administration of PPQ did not have any significant effect on the pharmacokinetics of CDRI 97-78.
Collapse
Affiliation(s)
- Muhammad Wahajuddin
- Pharmacokinetics and Metabolism Division, CSIR- Central Drug Research Institute, Lucknow, Uttar Pradesh, India.,Academy of Scientific and Industrial Research, New Delhi, India
| | - Sheelendra Pratap Singh
- Analytical Chemistry Division, CSIR-Indian Institute of Toxicology Research, Lucknow, Uttar Pradesh, India
| | - Isha Taneja
- Pharmacokinetics and Metabolism Division, CSIR- Central Drug Research Institute, Lucknow, Uttar Pradesh, India.,Academy of Scientific and Industrial Research, New Delhi, India
| | - Kanumuri Siva Rama Raju
- Pharmacokinetics and Metabolism Division, CSIR- Central Drug Research Institute, Lucknow, Uttar Pradesh, India.,Academy of Scientific and Industrial Research, New Delhi, India
| | - Jiaur Rahman Gayen
- Pharmacokinetics and Metabolism Division, CSIR- Central Drug Research Institute, Lucknow, Uttar Pradesh, India.,Academy of Scientific and Industrial Research, New Delhi, India
| | | | - Shio Kumar Singh
- Pharmacokinetics and Metabolism Division, CSIR- Central Drug Research Institute, Lucknow, Uttar Pradesh, India.,Academy of Scientific and Industrial Research, New Delhi, India
| |
Collapse
|
27
|
Wahajuddin M, Singh SP, Taneja I, Raju KSR, Gayen JR, Siddiqui HH, Singh SK. Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97-78 in rat plasma using the HPLC-ESI-MS/MS method: application to drug interaction study. Malar J 2015; 14:172. [PMID: 25895956 PMCID: PMC4429480 DOI: 10.1186/s12936-015-0684-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2014] [Accepted: 04/08/2015] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Lumefantrine is the mainstay of anti-malarial combination therapy in most endemic countries presently. However, it cannot be used alone owing to its long onset time of action. CDRI 97-78 is a promising trioxane-derivative anti-malarial candidate that is currently being investigated as a substitute for artemisinin derivatives owing to their emerging resistance. METHODS In the present study, a sensitive, simple and rapid high-performance liquid chromatography coupled with positive ion electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) method was developed for the simultaneous determination of lumefantrine and CDRI 97-78's metabolite, 97-63, in rat plasma using halofantrine as an internal standard. Lumefantrine and 97-63 were separated on a Waters Atlantis C18 (4.6×50 mm, 5.0 μm) column under isocratic condition with mobile phase consisting of acetonitrile: methanol (50:50, v/v) and ammonium formate buffer (10 mM, pH 4.5) in the ratio of 95:5 (v/v) at a flow rate of 0.65 mL/min. RESULTS The method was accurate and precise within the linearity range 3.9-500 ng/mL for both lumefantrine and 97-63 with a correlation coefficient (r2) of ≥0.998. The intra- and inter-day assay precision ranged from 2.24 to 7.14% and 3.97 to 5.90%, and intra- and inter-day assay accuracy was between 94.93 and 109.51% and 96.87 and 108.38%, respectively, for both the analytes. Upon coadministration of 97-78, the relative bioavailability of lumefantrine significantly decreased to 64.41%. CONCLUSIONS A highly sensitive, specific and reproducible high-throughput LC-ESI-MS/MS assay was developed and validated to quantify lumefantrine and CDRI 97-78. The method was successfully applied to study the effect of oral co-administration of lumefantrine on the pharmacokinetics of 97-78 in male Sprague-Dawley rats and vice versa. Co-administration of 97-78 significantly decreased the systemic exposure of lumefantrine.
Collapse
Affiliation(s)
- Muhammad Wahajuddin
- Academy of Scientific and Industrial Research, New Delhi, India. .,Pharmacokinetics and Metabolism Division, CSIR- Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India.
| | - Sheelendra P Singh
- Analytical Chemistry Division, CSIR-Indian Institute of Toxicology Research, Lucknow, 226001, Uttar Pradesh, India.
| | - Isha Taneja
- Academy of Scientific and Industrial Research, New Delhi, India. .,Pharmacokinetics and Metabolism Division, CSIR- Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India.
| | - Kanumuri S R Raju
- Academy of Scientific and Industrial Research, New Delhi, India. .,Pharmacokinetics and Metabolism Division, CSIR- Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India.
| | - Jiaur R Gayen
- Academy of Scientific and Industrial Research, New Delhi, India. .,Pharmacokinetics and Metabolism Division, CSIR- Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India.
| | | | - Shio K Singh
- Academy of Scientific and Industrial Research, New Delhi, India. .,Pharmacokinetics and Metabolism Division, CSIR- Central Drug Research Institute, Lucknow, 226031, Uttar Pradesh, India.
| |
Collapse
|
28
|
Singh S, Chauhan P, Ravi M, Taneja I, Wahajuddin W, Yadav PP. A mild CuBr–NMO oxidative system for the coupling of anilines leading to aromatic azo compounds. RSC Adv 2015. [DOI: 10.1039/c5ra12535a] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
An efficient methodology was developed for the synthesis of aromatic azo derivatives under mild reaction conditions utilizing CuBr with N-methylmorpholine N-oxide as an oxidant.
Collapse
Affiliation(s)
- Shikha Singh
- Division of Medicinal and Process Chemistry
- CSIR-Central Drug Research Institute
- Lucknow-226031
- India
| | - Parul Chauhan
- Division of Medicinal and Process Chemistry
- CSIR-Central Drug Research Institute
- Lucknow-226031
- India
| | - Makthala Ravi
- Division of Medicinal and Process Chemistry
- CSIR-Central Drug Research Institute
- Lucknow-226031
- India
| | - Isha Taneja
- Division of Pharmacokinetics and Metabolism
- CSIR-Central Drug Research Institute
- Lucknow-226031
- India
| | - Wahajuddin Wahajuddin
- Division of Pharmacokinetics and Metabolism
- CSIR-Central Drug Research Institute
- Lucknow-226031
- India
| | - Prem. P. Yadav
- Division of Medicinal and Process Chemistry
- CSIR-Central Drug Research Institute
- Lucknow-226031
- India
| |
Collapse
|
29
|
Taneja I, Raju KSR, Mittal M, Dev K, Khan MF, Maurya R, Wahajuddin M. Bioavailability, plasma protein binding and metabolic stability studies of a ALDH2 activator, alda-1, using a validated LC-ESI-MS/MS method in rat plasma. RSC Adv 2015. [DOI: 10.1039/c5ra06859b] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Alda-1 was found to be a poorly bioavailable, 82–86% protein bound, high extraction compound.
Collapse
Affiliation(s)
- Isha Taneja
- Academy of Scientific and Innovative Research
- New Delhi
- India
- Pharmacokinetics and Metabolism Division
- CSIR- Central Drug Research Institute
| | - Kanumuri Siva Rama Raju
- Academy of Scientific and Innovative Research
- New Delhi
- India
- Pharmacokinetics and Metabolism Division
- CSIR- Central Drug Research Institute
| | - Monika Mittal
- Division of Endocrinology
- CSIR- Central Drug Research Institute
- Lucknow
- India
| | - Kapil Dev
- Academy of Scientific and Innovative Research
- New Delhi
- India
- Medicinal and Process Chemistry Division
- CSIR- Central Drug Research Institute
| | - Mohammad Faheem Khan
- Academy of Scientific and Innovative Research
- New Delhi
- India
- Medicinal and Process Chemistry Division
- CSIR- Central Drug Research Institute
| | - Rakesh Maurya
- Academy of Scientific and Innovative Research
- New Delhi
- India
- Medicinal and Process Chemistry Division
- CSIR- Central Drug Research Institute
| | - Muhammad Wahajuddin
- Academy of Scientific and Innovative Research
- New Delhi
- India
- Pharmacokinetics and Metabolism Division
- CSIR- Central Drug Research Institute
| |
Collapse
|
30
|
Dwivedi P, Khatik R, Khandelwal K, Taneja I, Raju KSR, Wahajuddin, Paliwal SK, Dwivedi AK, Mishra PR. Pharmacokinetics study of arteether loaded solid lipid nanoparticles: an improved oral bioavailability in rats. Int J Pharm 2014; 466:321-7. [PMID: 24657144 DOI: 10.1016/j.ijpharm.2014.03.036] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2014] [Revised: 03/14/2014] [Accepted: 03/18/2014] [Indexed: 11/26/2022]
Abstract
Arteether (ART), an artemisinin derivative, is a life saving drug for multiple drug resistant malaria. It has a deliverance effect in Falciparum malaria and cerebral malaria. We have prepared solid lipid nanoparticles (SLN) by high pressure homogenization (HPH) technique. ART-loaded SLN (ART-SLN) has been produced reproducibly with homogeneous particle size. ART-SLN was characterized for their size measured by Zetasizer Nano-ZS, Malvern, UK and by high resolution transmission electron microscopy (HR-TEM) and which was found to be 100 ± 11.2 nm. The maximum percentage entrapment efficiency (%EE) determined with the high-performance liquid chromatography (HPLC) has been found to be 69 ± 4.2% in ART-SLN-3. The release pattern from ART-SLN revealed that the release of ART is slow but time-dependent manner, which is desirable as it will help to protect the acid degradation of ART in stomach. The percentage cytotoxicity of blank SLN has been found within the acceptable range. The pharmacokinetics results indicated that ART-SLN-3 absorption has been significantly enhanced in comparison to ART in aqueous suspension and ART in ground nut oil (GNO) in rats. The % relative bioavailability (RB%) of ART-SLN to the ART in GNO and ART in aqueous suspension in rats was 169.99% and 7461%, respectively which was found to be significantly high in both the cases. From the results, it can be concluded that ART-SLN offers a new approach to improve the oral bioavailability of ART.
Collapse
Affiliation(s)
- Pankaj Dwivedi
- Pharmaceutics Division, Central Drug Research Institute, Lucknow 226031, India.
| | - Renuka Khatik
- Pharmaceutics Division, Central Drug Research Institute, Lucknow 226031, India
| | - Kiran Khandelwal
- Pharmaceutics Division, Central Drug Research Institute, Lucknow 226031, India
| | - Isha Taneja
- Pharmacokinetics and Metabolism Division, Central Drug Research Institute, Lucknow 226031, India
| | - Kanumuri Siva Rama Raju
- Pharmacokinetics and Metabolism Division, Central Drug Research Institute, Lucknow 226031, India
| | - Wahajuddin
- Pharmacokinetics and Metabolism Division, Central Drug Research Institute, Lucknow 226031, India
| | | | - Anil Kumar Dwivedi
- Pharmaceutics Division, Central Drug Research Institute, Lucknow 226031, India
| | | |
Collapse
|
31
|
Dwivedi P, Khatik R, Khandelwal K, Srivastava R, Taneja I, Rama Raju KS, Dwivedi H, Shukla P, Gupta P, Singh S, Tripathi R, Paliwal SK, Wahajuddin W, Dwivedi AK, Mishra PR. Self-nanoemulsifying drug delivery systems (SNEDDS) for oral delivery of arteether: pharmacokinetics, toxicity and antimalarial activity in mice. RSC Adv 2014. [DOI: 10.1039/c4ra09267h] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
The nontoxic SNEDDS of arteether, improved arteether bioavailability and anti-malarial efficacy.
Collapse
Affiliation(s)
- Pankaj Dwivedi
- Pharmaceutics Division
- Central Drug Research Institute
- Lucknow 226031, India
- Banasthali Vidyapeeth
- Banasthali, India
| | - Renuka Khatik
- Pharmaceutics Division
- Central Drug Research Institute
- Lucknow 226031, India
| | - Kiran Khandelwal
- Pharmaceutics Division
- Central Drug Research Institute
- Lucknow 226031, India
| | - Richa Srivastava
- Pharmaceutics Division
- Central Drug Research Institute
- Lucknow 226031, India
| | - Isha Taneja
- Pharmacokinetics and Metabolism Division
- Central Drug Research Institute
- Lucknow 226031, India
| | - Kanumuri Siva Rama Raju
- Pharmacokinetics and Metabolism Division
- Central Drug Research Institute
- Lucknow 226031, India
| | - Hemlata Dwivedi
- Parasitology Division
- Central Drug Research Institute
- Lucknow 226031, India
| | - Prashant Shukla
- Pharmaceutics Division
- Central Drug Research Institute
- Lucknow 226031, India
| | - Pramod Gupta
- Pharmaceutics Division
- Central Drug Research Institute
- Lucknow 226031, India
| | - Sarika Singh
- Toxicology Division
- Central Drug Research Institute
- Lucknow 226031, India
| | - Renu Tripathi
- Parasitology Division
- Central Drug Research Institute
- Lucknow 226031, India
| | | | - Wahajuddin Wahajuddin
- Pharmacokinetics and Metabolism Division
- Central Drug Research Institute
- Lucknow 226031, India
| | - Anil Kumar Dwivedi
- Pharmaceutics Division
- Central Drug Research Institute
- Lucknow 226031, India
| | | |
Collapse
|
32
|
Wahajuddin, Raju KSR, Singh SP, Taneja I. Investigation of the functional role of P-glycoprotein in limiting the oral bioavailability of lumefantrine. Antimicrob Agents Chemother 2013; 58:489-94. [PMID: 24189249 PMCID: PMC3910766 DOI: 10.1128/aac.01382-13] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2013] [Accepted: 10/27/2013] [Indexed: 11/20/2022] Open
Abstract
In the quest to explore the reason for the low and variable bioavailability of lumefantrine, we investigated the possible role of P-glycoprotein (P-gp) in lumefantrine intestinal absorption. An in situ single-pass intestinal perfusion study in rats with the P-gp inhibitor verapamil or quinidine and an ATPase assay with human P-gp membranes indicated that lumefantrine is a substrate of P-gp which limits its intestinal absorption. To confirm these findings, an in vivo pharmacokinetic study was performed in rats. The oral administration of verapamil (10 mg/kg of body weight) along with lumefantrine caused a significant increase in its bioavailability with a concomitant decrease in clearance. The increase in bioavailability of lumefantrine could be due to inhibition of P-gp and/or cytochrome P450 3A in the intestine/liver by verapamil. However, in a rat intestinal microsomal stability study, lumefantrine was found to be resistant to oxidative metabolism. Further, an in situ permeation study clearly showed a significant role of P-gp in limiting the oral absorption of lumefantrine. Thus, the increase in lumefantrine bioavailability with verapamil is attributed in part to the P-gp-inhibitory ability of verapamil. In conclusion, lumefantrine is a substrate of P-gp, and active efflux by P-gp across the intestine partly contributed to the low/variable bioavailability of lumefantrine.
Collapse
Affiliation(s)
- Wahajuddin
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India
| | | | | | | |
Collapse
|
33
|
Wahajuddin, Taneja I, Arora S, Raju KSR, Siddiqui N. Disposition of pharmacologically active dietary isoflavones in biological systems. Curr Drug Metab 2013; 14:369-80. [PMID: 23330931 DOI: 10.2174/1389200211314040002] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2012] [Revised: 10/23/2012] [Accepted: 10/25/2012] [Indexed: 11/22/2022]
Abstract
Dietary isoflavones, popularly known as phytoestrogens, represent one of the most biologically active classes of flavonoids. Numerous in vitro and in vivo studies provide convincing evidence regarding their beneficial effects on human health. These isoflavones are increasingly being investigated as potential alternate therapies for a range of hormone-dependent conditions, including cancer, menopausal symptoms, osteoporosis and cardiovascular diseases. However, they exhibit poor oral bioavailability which limits their clinical utility in humans. The reason being, they are substrates of a plethora of enzymes and transporters and undergo extensive conjugative metabolism which facilitates their rapid elimination from biological systems. In addition, a number of experimental studies have also revealed that these isoflavones are potent inhibitors of various cytochrome P450 isoforms and transporters which play an important role in the disposition of many commonly prescribed drugs. Thus, there arise chances of observing clinically relevant herb-drug interactions which could sometimes be life-threatening. This review gives a comprehensive understanding of these dietary phytoestrogens with regard to their absorption, biodistribution and the role of enzyme-transporter interplay affecting their disposition in biological systems. Further, the effects of these phytoestrogens on the activity and kinetics of drug metabolizing enzymes and various clinically relevant influx/efflux transporters and the resulting diet-drug interactions have also been discussed.
Collapse
Affiliation(s)
- Wahajuddin
- Academy of Scientific and Innovative Research, New Delhi, India.
| | | | | | | | | |
Collapse
|
34
|
Raju KSR, Taneja I, Singh SP, Wahajuddin. Utility of noninvasive biomatrices in pharmacokinetic studies. Biomed Chromatogr 2013; 27:1354-66. [PMID: 23939915 DOI: 10.1002/bmc.2996] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2013] [Revised: 06/12/2013] [Accepted: 06/13/2013] [Indexed: 12/31/2022]
Abstract
Blood and plasma are the biomatrices traditionally used for drug monitoring and their pharmacokinetic profiling. Blood is the circulating fluid in contact with all organs and tissues of body and thus is the most representative fluid for measuring systemic drug levels. However, venipuncture suffers from the caveat of being an invasive technique which often makes people reluctant to participate in clinical studies. Thus, there is a need for noninvasive bio-fluids that are ethically appropriate, cost-efficient and toxicologically relevant. These alternate bio-fluids may prove clinically useful as alternatives to plasma/serum in therapeutic drug monitoring, pharmacokinetic and toxicokinetic studies, doping control in sports medicine and to monitor local adverse effects. These may be of particular interest in the case of special population groups such as neonates, children, the elderly, terminally ill patients and pregnant or lactating women, and offer the advantage of circumvention of the demand for specialized personnel for sample collection. This review describes such noninvasive bio-fluids (saliva, sweat, tears and milk) that have been considered for pharmacokinetic drug analysis, emphasizing their sample preparation, its associated difficulties and their correlation with plasma.
Collapse
Affiliation(s)
- Kanumuri Siva Rama Raju
- Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow-226021, India
| | | | | | | |
Collapse
|
35
|
Maurya R, Soni A, Anand D, Ravi M, Raju KSR, Taneja I, Naikade NK, Puri SK, Wahajuddin, Kanojiya S, Yadav PP. Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes. ACS Med Chem Lett 2013; 4:165-9. [PMID: 24900640 DOI: 10.1021/ml300188t] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2012] [Accepted: 12/11/2012] [Indexed: 11/30/2022] Open
Abstract
Novel 3,3-spiroanellated 5-aryl, 6-arylvinyl-substituted 1,2,4-trioxanes 19-34 have been synthesized and appraised for their antimalarial activity against multidrug-resistant Plasmodium yoelii nigeriensis in Swiss mice by oral route at doses ranging from 96 mg/kg × 4 days to 24 mg/kg × 4 days. The most active compound of the series (compound 25) provided 100% protection at 24 mg/kg × 4 days, and other 1,2,4-trioxanes 22, 26, 27, and 30 also showed promising activity. In this model, β-arteether provided 100 and 20% protection at 48 mg/kg × 4 days and 24 mg/kg × 4 days, respectively, by oral route. Compound 25 displayed a similar in vitro pharmacokinetic profile to that of reference drug β-arteether. The activity results demonstrated the importance of an aryl moiety at the C-5 position on the 1,2,4-trioxane pharmacophore.
Collapse
Affiliation(s)
- Ranjani Maurya
- Division of Medicinal & Process Chemistry, ‡Division of Parasitology, §Division of Pharmacokinetics and Metabolism, and ∥Sophisticated Analytical Instrument Facility, Central Drug Research Institute, Lucknow-226001, India
| | - Awakash Soni
- Division of Medicinal & Process Chemistry, ‡Division of Parasitology, §Division of Pharmacokinetics and Metabolism, and ∥Sophisticated Analytical Instrument Facility, Central Drug Research Institute, Lucknow-226001, India
| | - Devireddy Anand
- Division of Medicinal & Process Chemistry, ‡Division of Parasitology, §Division of Pharmacokinetics and Metabolism, and ∥Sophisticated Analytical Instrument Facility, Central Drug Research Institute, Lucknow-226001, India
| | - Makthala Ravi
- Division of Medicinal & Process Chemistry, ‡Division of Parasitology, §Division of Pharmacokinetics and Metabolism, and ∥Sophisticated Analytical Instrument Facility, Central Drug Research Institute, Lucknow-226001, India
| | - Kanumuri S. R. Raju
- Division of Medicinal & Process Chemistry, ‡Division of Parasitology, §Division of Pharmacokinetics and Metabolism, and ∥Sophisticated Analytical Instrument Facility, Central Drug Research Institute, Lucknow-226001, India
| | - Isha Taneja
- Division of Medicinal & Process Chemistry, ‡Division of Parasitology, §Division of Pharmacokinetics and Metabolism, and ∥Sophisticated Analytical Instrument Facility, Central Drug Research Institute, Lucknow-226001, India
| | - Niraj K. Naikade
- Division of Medicinal & Process Chemistry, ‡Division of Parasitology, §Division of Pharmacokinetics and Metabolism, and ∥Sophisticated Analytical Instrument Facility, Central Drug Research Institute, Lucknow-226001, India
| | - S. K. Puri
- Division of Medicinal & Process Chemistry, ‡Division of Parasitology, §Division of Pharmacokinetics and Metabolism, and ∥Sophisticated Analytical Instrument Facility, Central Drug Research Institute, Lucknow-226001, India
| | - Wahajuddin
- Division of Medicinal & Process Chemistry, ‡Division of Parasitology, §Division of Pharmacokinetics and Metabolism, and ∥Sophisticated Analytical Instrument Facility, Central Drug Research Institute, Lucknow-226001, India
| | - Sanjeev Kanojiya
- Division of Medicinal & Process Chemistry, ‡Division of Parasitology, §Division of Pharmacokinetics and Metabolism, and ∥Sophisticated Analytical Instrument Facility, Central Drug Research Institute, Lucknow-226001, India
| | - Prem P. Yadav
- Division of Medicinal & Process Chemistry, ‡Division of Parasitology, §Division of Pharmacokinetics and Metabolism, and ∥Sophisticated Analytical Instrument Facility, Central Drug Research Institute, Lucknow-226001, India
| |
Collapse
|
36
|
|